

**conjugated estrogen 0.3mg tablet (Premarin<sup>®</sup>) No. (413/07)**  
**Wyeth Pharmaceuticals**

Product Update

5 October 2007

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**conjugated estrogens 0.3mg tablet (Premarin<sup>®</sup>)** is accepted for use within NHS Scotland as hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women.

It should be used for patients in whom conjugated estrogens is an appropriate choice of hormone replacement therapy and in whom the lower dose preparation provides adequate control of symptoms.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 3 September 2007.*

**Chairman,  
Scottish Medicines Consortium**